Skip to main content
RECOVER: Researching COVID to Enhance Recovery Home
En Español
Esta página web solamente está disponible en ingles en este momento. Apreciamos su paciencia mientras traducimos el contenido de nuestra página.

Sharing science to find answers

Find RECOVER Publications

Researchers within the RECOVER Initiative share their progress to understand, treat, and prevent Long COVID through research publications. Follow the latest science from RECOVER’s research studies below.

Visit the Research Summaries page to learn about RECOVER’s Long COVID research in a format that’s easy to understand.

Last updated:

116 Results

Filters

116 Results

Filters Applied:
Observational Pediatric

Researching COVID to enhance recovery (RECOVER) pediatric study protocol: Rationale, objectives and design

Gross, RS; Thaweethai, T; Rosenzweig, EB; et. al.RECOVER-Pediatric Consortium, PLOS ONE,
Summary
Pathobiology Review

The potency of hematopoietic stem cell reprogramming for changing immune tone

Daman, AW; Cheong, JG; Berneking, L; Josefowicz, SZ, Immunological Reviews,
EHR Pediatric Risk Factors

Learning competing risks across multiple hospitals: One-shot distributed algorithms

Zhang, D; Tong, J; Jing, N; et al., Journal of the American Medical Informatics Association,
Summary
EHR Adult Pediatric

Long COVID incidence in adults and children between 2020 and 2023: A real-world data study from the RECOVER Initiative

Mandel, H; Yoo, Y; Allen, A; et al., Research Square,
Preprint
Pathobiology

Characteristics and determinants of pulmonary Long COVID

Patton, MJ; Benson, D; Robison, SW; et al., JCI Insight,
EHR Adult

Effect of Paxlovid treatment during acute COVID-19 on Long COVID onset: An EHR-based target trial emulation from the N3C and RECOVER Consortia

Preiss, A; Bhatia, A; Aragon, LV; et al., medRxiv,
Preprint
Review Pediatric New-onset and Pre-existing Conditions Risk Factors Viral Variants

Postacute sequelae of SARS-CoV-2 in children

Rao, S; Gross, RS; Mohandas, S; et al., Pediatrics,
Summary
Pathobiology

Autoantibodies to ACE2 and immune molecules are associated with COVID-19 disease severity

Geanes, ES; McLennan, R; LeMaster, C; , Communications Medicine,
Pathobiology

The S1 subunits of SARS-CoV-2 variants differentially trigger the IL-6 signaling pathway in human brain endothelial cells and downstream impact on microglia activation

Stangis, M; Adesse, D; Sharma, B; et al., NeuroImmune Pharmacology and Therapeutics,
Back to Top